JP2021504338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504338A5 JP2021504338A5 JP2020528129A JP2020528129A JP2021504338A5 JP 2021504338 A5 JP2021504338 A5 JP 2021504338A5 JP 2020528129 A JP2020528129 A JP 2020528129A JP 2020528129 A JP2020528129 A JP 2020528129A JP 2021504338 A5 JP2021504338 A5 JP 2021504338A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- crystalline
- angles
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCN(CC*)CC1CC1 Chemical compound CCCN(CC*)CC1CC1 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076364A JP2023093762A (ja) | 2017-11-22 | 2023-05-02 | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589822P | 2017-11-22 | 2017-11-22 | |
| US62/589,822 | 2017-11-22 | ||
| US201862691709P | 2018-06-29 | 2018-06-29 | |
| US62/691,709 | 2018-06-29 | ||
| PCT/US2018/062197 WO2019104134A1 (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076364A Division JP2023093762A (ja) | 2017-11-22 | 2023-05-02 | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504338A JP2021504338A (ja) | 2021-02-15 |
| JP2021504338A5 true JP2021504338A5 (enExample) | 2023-01-30 |
| JP7275130B2 JP7275130B2 (ja) | 2023-05-17 |
Family
ID=64734113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528129A Active JP7275130B2 (ja) | 2017-11-22 | 2018-11-21 | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
| JP2023076364A Withdrawn JP2023093762A (ja) | 2017-11-22 | 2023-05-02 | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076364A Withdrawn JP2023093762A (ja) | 2017-11-22 | 2023-05-02 | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11254652B2 (enExample) |
| EP (2) | EP4285904A3 (enExample) |
| JP (2) | JP7275130B2 (enExample) |
| KR (3) | KR102682430B1 (enExample) |
| CN (2) | CN117551030A (enExample) |
| AU (3) | AU2018373122B2 (enExample) |
| BR (1) | BR112020010185A2 (enExample) |
| CA (1) | CA3081945A1 (enExample) |
| DK (1) | DK3713919T3 (enExample) |
| ES (1) | ES2959764T3 (enExample) |
| FI (1) | FI3713919T3 (enExample) |
| HR (1) | HRP20230931T1 (enExample) |
| HU (1) | HUE063264T2 (enExample) |
| IL (3) | IL274488B2 (enExample) |
| LT (1) | LT3713919T (enExample) |
| MD (1) | MD3713919T2 (enExample) |
| MX (2) | MX2020005348A (enExample) |
| PH (1) | PH12020550644A1 (enExample) |
| PL (1) | PL3713919T3 (enExample) |
| PT (1) | PT3713919T (enExample) |
| RS (1) | RS64592B1 (enExample) |
| SG (1) | SG11202004587XA (enExample) |
| SI (1) | SI3713919T1 (enExample) |
| SM (1) | SMT202300327T1 (enExample) |
| TW (2) | TWI922809B (enExample) |
| UA (1) | UA127502C2 (enExample) |
| WO (1) | WO2019104134A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| KR102682430B1 (ko) | 2017-11-22 | 2024-07-08 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태 |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| JP2022533227A (ja) * | 2019-05-22 | 2022-07-21 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性塩形態 |
| US11878049B1 (en) | 2019-06-14 | 2024-01-23 | Agios Pharmaceuticals, Inc. | Mitapivat therapy and modulators of cytochrome P450 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| US12286404B2 (en) * | 2020-01-28 | 2025-04-29 | Teva Pharmaceuticals International Gmbh | Solid state forms of Mitapivat and process for preparation thereof |
| CN116568281A (zh) * | 2020-09-25 | 2023-08-08 | 安吉奥斯医药品有限公司 | 药物制剂 |
| CA3196829A1 (en) * | 2020-09-25 | 2022-03-31 | Agios Pharmaceuticals, Inc. | Pharmaceutical formulation |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4329758A1 (en) | 2021-04-30 | 2024-03-06 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
| WO2023154036A1 (en) * | 2022-02-08 | 2023-08-17 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
| WO2022231627A1 (en) | 2021-04-30 | 2022-11-03 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat for use in treating thalassemia |
| EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
| KR20240107326A (ko) | 2021-11-16 | 2024-07-09 | 아지오스 파마슈티컬스 아이엔씨. | Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물 |
| US20260146025A1 (en) | 2022-10-17 | 2026-05-28 | Tianish Laboratories Private Limited | Crystalline polymorphs of mitapivat and mitapivat hemisulfate |
| ES2975743A1 (es) * | 2022-11-22 | 2024-07-12 | Moehs Iberica Sl | Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos |
| WO2024228131A1 (en) * | 2023-05-02 | 2024-11-07 | Biophore India Pharmaceuticals Pvt. Ltd | Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof |
| WO2025008787A1 (en) * | 2023-07-05 | 2025-01-09 | Biophore India Pharmaceuticals Pvt. Ltd | Solid forms of mitapivat hemisulfate |
| WO2025083627A1 (en) * | 2023-10-18 | 2025-04-24 | Apitoria Pharma Private Limited | Novel crystalline forms of mitapivat sulfate and processes for preparation |
| WO2025146636A1 (en) * | 2024-01-03 | 2025-07-10 | Tianish Laboratories Private Limited | Novel crystalline polymorphs of mitapivat sulfate salt |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000510866A (ja) | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド |
| IN191496B (enExample) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| US20010041706A1 (en) | 2000-03-24 | 2001-11-15 | Synold Timothy W. | Blockade of taxane metabolism |
| AU2001288690A1 (en) | 2000-09-05 | 2002-03-22 | Odyssey Pharmaceuticals Llc | Two-component anti-emetic composition comprising dexamethasone and metoclopramide |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| US20140162942A1 (en) | 2010-07-30 | 2014-06-12 | Anima Ghosal | Inhibition of cyp3a drug metabolism |
| PT3406251T (pt) | 2011-05-03 | 2024-01-24 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| US20140249150A1 (en) * | 2011-10-13 | 2014-09-04 | Agios Pharmaceuticals, Inc | Activators of pyruvate kinase m2 and methods of treating disease |
| EP2877214B1 (en) * | 2012-07-26 | 2019-04-24 | Joslin Diabetes Center, Inc. | Predicting diabetic complications |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| JP2017513921A (ja) | 2014-03-03 | 2017-06-01 | アーチャルジー、スジャータ | ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質 |
| MX384883B (es) * | 2015-06-11 | 2025-03-14 | Agios Pharmaceuticals Inc | Métodos para usar activadores de piruvato cinasa. |
| KR102682430B1 (ko) | 2017-11-22 | 2024-07-08 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태 |
| US11878049B1 (en) | 2019-06-14 | 2024-01-23 | Agios Pharmaceuticals, Inc. | Mitapivat therapy and modulators of cytochrome P450 |
-
2018
- 2018-11-21 KR KR1020207015018A patent/KR102682430B1/ko active Active
- 2018-11-21 PT PT188217798T patent/PT3713919T/pt unknown
- 2018-11-21 FI FIEP18821779.8T patent/FI3713919T3/fi active
- 2018-11-21 MD MDE20200988T patent/MD3713919T2/ro unknown
- 2018-11-21 US US16/765,456 patent/US11254652B2/en active Active
- 2018-11-21 CA CA3081945A patent/CA3081945A1/en active Pending
- 2018-11-21 SI SI201830984T patent/SI3713919T1/sl unknown
- 2018-11-21 CN CN202311301795.5A patent/CN117551030A/zh active Pending
- 2018-11-21 SG SG11202004587XA patent/SG11202004587XA/en unknown
- 2018-11-21 IL IL274488A patent/IL274488B2/en unknown
- 2018-11-21 CN CN201880075099.8A patent/CN111372920B/zh active Active
- 2018-11-21 WO PCT/US2018/062197 patent/WO2019104134A1/en not_active Ceased
- 2018-11-21 IL IL305343A patent/IL305343B2/en unknown
- 2018-11-21 EP EP23186155.0A patent/EP4285904A3/en active Pending
- 2018-11-21 AU AU2018373122A patent/AU2018373122B2/en active Active
- 2018-11-21 UA UAA202003680A patent/UA127502C2/uk unknown
- 2018-11-21 JP JP2020528129A patent/JP7275130B2/ja active Active
- 2018-11-21 LT LTEPPCT/US2018/062197T patent/LT3713919T/lt unknown
- 2018-11-21 SM SM20230327T patent/SMT202300327T1/it unknown
- 2018-11-21 RS RS20230793A patent/RS64592B1/sr unknown
- 2018-11-21 MX MX2020005348A patent/MX2020005348A/es unknown
- 2018-11-21 DK DK18821779.8T patent/DK3713919T3/da active
- 2018-11-21 TW TW112118933A patent/TWI922809B/zh active
- 2018-11-21 TW TW107141542A patent/TWI808108B/zh active
- 2018-11-21 HU HUE18821779A patent/HUE063264T2/hu unknown
- 2018-11-21 KR KR1020247022172A patent/KR102777452B1/ko active Active
- 2018-11-21 IL IL322576A patent/IL322576A/en unknown
- 2018-11-21 KR KR1020257007025A patent/KR20250034202A/ko active Pending
- 2018-11-21 PL PL18821779.8T patent/PL3713919T3/pl unknown
- 2018-11-21 BR BR112020010185-0A patent/BR112020010185A2/pt unknown
- 2018-11-21 HR HRP20230931TT patent/HRP20230931T1/hr unknown
- 2018-11-21 ES ES18821779T patent/ES2959764T3/es active Active
- 2018-11-21 EP EP18821779.8A patent/EP3713919B1/en active Active
-
2020
- 2020-05-15 PH PH12020550644A patent/PH12020550644A1/en unknown
- 2020-07-13 MX MX2022009998A patent/MX2022009998A/es unknown
-
2022
- 2022-01-14 US US17/575,898 patent/US12612381B2/en active Active
-
2023
- 2023-05-02 JP JP2023076364A patent/JP2023093762A/ja not_active Withdrawn
-
2024
- 2024-02-06 AU AU2024200724A patent/AU2024200724B2/en active Active
-
2026
- 2026-03-26 US US19/629,456 patent/US20260217676A1/en active Pending
- 2026-04-29 AU AU2026203244A patent/AU2026203244A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7275130B2 (ja) | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 | |
| US10596158B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| JP2023532257A5 (enExample) | ||
| TWI496773B (zh) | Ｎ－［２－［［（２，３－二氟苯基）甲基］硫基］－６－｛［（１ｒ，２ｓ）－２，３－二羥基－１－甲基丙基］氧基｝－４－嘧啶基］－１－三亞甲亞胺磺醯胺之新穎結晶型 | |
| CN115427112B (zh) | 2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钾盐 | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
| US12492192B2 (en) | Crystalline form of lifitegrast, and pharmaceutical composition comprising the same | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| JP2022533227A5 (enExample) | ||
| WO2010111951A1 (zh) | 普拉格雷氢溴酸盐的晶体 | |
| WO2016146020A1 (zh) | 尼达尼布二乙磺酸盐晶体及其制备方法和用途 | |
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| DK170234B1 (da) | Hydrochloridhydrat af Endo-4-amino-5-chlor-2-methoxy-N-(1'-azabicyclo-[3.3.1]-non-4'-yl)-benzamid, fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende forbindelsen samt anvendelse af forbindelsen | |
| NL1014634C1 (nl) | Zolpidemzouten. | |
| JP2013535475A (ja) | フマル酸テノホビルジソプロキシルの結晶 | |
| NZ805778A (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1- carbonyl)phenyl)quinoline-8-sulfonamide | |
| EA052982B1 (ru) | Твердые формы соединения для лечения или профилактики гиперурикемии или подагры | |
| JP2023121422A (ja) | 保存安定性が改善されたニロチニブ塩酸塩含有カプセル剤 | |
| CN104072476A (zh) | 泊马度胺晶型及其制备方法和用途 | |
| BR112019023592A2 (pt) | Formas cristalinas de seletalisibe | |
| HK1227389A1 (en) | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof |